H Phillip Koeffler
Overview
Explore the profile of H Phillip Koeffler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
416
Citations
17416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wang R, Mi Y, Ni J, Wang Y, Ding L, Ran X, et al.
Adv Sci (Weinh)
. 2023 Dec;
11(9):e2304939.
PMID: 38115765
Treatment of castration-resistant prostate cancer (CRPC) is a long-standing clinical challenge. Traditionally, CRPC drugs work by either reducing dihydrotestosterone biosynthesis or blocking androgen receptor (AR) signaling. Here it is demonstrated...
12.
Zhang L, Zheng Y, Chien W, Ziman B, Billet S, Koeffler H, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001638
ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the...
13.
Hazawa M, Ikliptikawati D, Iwashima Y, Lin D, Jiang Y, Qiu Y, et al.
Cell Chem Biol
. 2023 Nov;
31(4):792-804.e7.
PMID: 37924814
Master transcription factors such as TP63 establish super-enhancers (SEs) to drive core transcriptional networks in cancer cells, yet the spatiotemporal regulation of SEs within the nucleus remains unknown. The nuclear...
14.
Zheng Y, Ziman B, Ho A, Sinha U, Xu L, Li E, et al.
Genome Biol
. 2023 Aug;
24(1):193.
PMID: 37620896
Background: As one of the most common malignancies, esophageal cancer has two subtypes, squamous cell carcinoma and adenocarcinoma, arising from distinct cells-of-origin. Distinguishing cell-type-specific molecular features from cancer-specific characteristics is...
15.
Madan V, Shyamsunder P, Dakle P, Woon T, Han L, Cao Z, et al.
Blood Adv
. 2023 Aug;
7(21):6553-6566.
PMID: 37611161
The adenosine triphosphate (ATP)-dependent chromatin remodeling complex, SWItch/Sucrose Non-Fermentable (SWI/SNF), has been implicated in normal hematopoiesis. The AT-rich interaction domain 1B (ARID1B) and its paralog, ARID1A, are mutually exclusive, DNA-interacting...
16.
Chien W, Tyner J, Gery S, Zheng Y, Li L, Gopinatha Pillai M, et al.
J Ovarian Res
. 2023 Apr;
16(1):80.
PMID: 37087441
Background: Standard platinum-based therapy for ovarian cancer is inefficient against ovarian clear cell carcinoma (OCCC). OCCC is a distinct subtype of epithelial ovarian cancer. OCCC constitutes 25% of ovarian cancers...
17.
Kusuma F, Prabhu A, Tieo G, Ahmed S, Dakle P, Yong W, et al.
Nat Commun
. 2023 Apr;
14(1):1919.
PMID: 37024489
Alternative lengthening of telomeres (ALT) supports telomere maintenance in 10-15% of cancers, thus representing a compelling target for therapy. By performing anti-cancer compound library screen on isogenic cell lines and...
18.
Li Y, Chen H, Lu D, Koeffler H, Zhang Y, Yin D
Autophagy
. 2023 Feb;
19(9):2618-2619.
PMID: 36747349
Drug-tolerant persister (DTP) cancer cells drive residual tumor and relapse. However, the mechanisms underlying DTP state development are largely unexplored. In a recent study, we determined that PINK1-mediated mitophagy favors...
19.
Ran X, Ding L, Sun Q, Yang H, Said J, Zhentang L, et al.
Cancer Res
. 2023 Jan;
83(6):922-938.
PMID: 36638333
Significance: Targeting XRN1 activates an intracellular innate immune response mediated by RNA-sensing signaling and potentiates cancer immunotherapy efficacy, suggesting inhibition of RNA decay machinery as a novel strategy for cancer...
20.
Li Y, Chen H, Xie X, Yang B, Wang X, Zhang J, et al.
Cancer Res
. 2022 Dec;
83(3):398-413.
PMID: 36480196
Significance: DTP cancer cells that cause relapse after anticancer therapy critically depend on PINK1-mediated mitophagy and metabolic reprogramming, providing a therapeutic opportunity to eradicate persister cells to prolong treatment efficacy.